Bremelanotide directly improved desire and reduced distress in premenopausal women with acquired, generalized HSDD. Rebody turns that melanocortin active into two needle-free routines: a seconds-long nasal spray and a compact mini troche. The phase 3 evidence used FDA-approved Vyleesi injection, so each Rebody route keeps its own dose and timing.
Current Rebody pricing: PT-141 nasal spray is $99.50 for the first month, then $199 per 5 mL bottle. PT-141 troches are $54.50 for the first month, then $109 per 8-count package for 1 mg; $59.50 for the first month, then $119 for 2 mg.
The short answer
Low desire becomes a medical-treatment question when the change is persistent, generalized, personally distressing, and not better explained by another condition, medication, substance, or relationship problem. That is the population studied in the pivotal bremelanotide trials.
The active is not a hormone and not “female Viagra.” It acts through central melanocortin pathways involved in desire and arousal. It does not directly correct vaginal dryness, pain with sex, a medication side effect, low estrogen, relationship conflict, or every reason intimacy changes.
Bremelanotide formats at a glance
| Format | Strength / package | Storage | Evidence position |
|---|---|---|---|
| Vyleesi injection | 1.75 mg single-dose autoinjector | Follow approved label | FDA-approved; pivotal HSDD trials |
| PT-141 nasal spray | 5 or 10 mg/mL in 5 mL bottle | Refrigerated | Small intranasal studies; Rebody bottle not directly tested |
| PT-141 mini troche | 1 or 2 mg, 10 count | Refrigerated | No route-specific clinical outcome trial identified |
The Rebody nasal and troche products are available at $99.50 first month, then $199 per 5 mL bottle and $54.50 first month, then $109 per 8-count package for 1 mg; $59.50 first month, then $119 for 2 mg. Final route dose, timing, uses per package, and refill details remain prescription-specific.
What acquired, generalized HSDD means
“Acquired” means desire changed from a previous level rather than always being low. “Generalized” means the concern is not limited to one partner, one situation, or one kind of sexual activity. HSDD also requires personal distress.
That last point matters. A woman does not need medication because her desire differs from a partner's expectation or a cultural ideal. The symptom belongs to her when she experiences it as a loss or problem.
The approved Vyleesi label also excludes low desire better explained by another medical or psychiatric condition, relationship problem, or medication or substance effect. Those explanations can lead to entirely different solutions.
What the RECONNECT trials found
The two phase 3 RECONNECT trials randomized 1,267 premenopausal women with acquired, generalized HSDD. Participants used 1.75 mg subcutaneous bremelanotide as needed for 24 weeks.
Bremelanotide improved the Female Sexual Function Index desire-domain score and reduced distress related to low desire compared with placebo. The co-primary satisfying-sexual-event outcome did not improve significantly.
That result is strong and specific. Bremelanotide affected desire and distress in the studied population. It should not be rewritten as guaranteed orgasm, lubrication, more sex, or relationship repair.
What bremelanotide is not fixing
Pain can suppress desire. Vaginal dryness, genitourinary syndrome of menopause, pelvic-floor dysfunction, infection, endometriosis, and vulvar conditions may make sexual activity uncomfortable. Treating desire while pain remains can miss the problem entirely.
Antidepressants and other medications can affect desire or arousal. Depression, anxiety, sleep loss, postpartum change, menopause, chronic illness, body image, trauma, and relationship dynamics can also matter.
Bremelanotide is most coherent when the central complaint is acquired, generalized desire loss with distress—not when another untreated driver is obvious.
Best-supported option: Vyleesi injection
The approved injection wins on evidence because the finished product, population, dose, and endpoints were tested in phase 3 trials. Its label specifies use at least 45 minutes before anticipated sexual activity and sets maximum frequency.
It also creates injection burden and injection-site reactions. A woman who will not use a needle can have a perfectly rational reason to investigate another route.
Do not describe a nasal bottle or troche as generic Vyleesi. They contain bremelanotide but differ in route and finished formulation.
Best needle-free practical option: nasal spray
The nasal bottle is the simplest Rebody format. Administration can take seconds, and there is no oral dissolve period. The available presentation is 10 mg/mL in a refrigerated 5 mL bottle.
One small crossover experiment studied a 20 mg intranasal dose in 18 premenopausal women with female sexual arousal disorder. It was not a pivotal HSDD trial and did not test either finished Rebody bottle.
The pharmacy label supplies pump output, sprays per dose, priming, timing, and maximum frequency. Do not derive any of them from the concentration printed on the bottle.
Best compact oral-dissolve format: troche
The available 1 mg and 2 mg mini troches dissolve under the tongue or between gum and cheek. They avoid needles, pump technique, congestion, and nasal runoff.
There is no direct route-specific outcome trial for the troches. Follow the dispensed directions for placement, dissolve time, food and drink spacing, timing, and maximum use.
Choose troche for route preference. Do not present sublingual or buccal placement as proof of rapid, complete, or injection-equivalent absorption.
Desire, arousal, lubrication, and orgasm
Desire is interest or motivation. Arousal includes subjective excitement and physiological response. Lubrication is one physiological response. Orgasm is another outcome entirely.
These can influence each other without moving together. A desire medication can increase interest while pain or dryness remains. A lubricant can improve comfort without changing desire. An erection drug can improve blood flow without producing sexual interest.
The measured outcomes matter: the RECONNECT trials found changes in desire and distress. They did not establish a guaranteed sequence of arousal, lubrication, intercourse, and orgasm.
Premenopause, menopause, and population boundaries
Vyleesi's approved indication is premenopausal women with acquired, generalized HSDD. It is not indicated for postmenopausal women or men under the cited label.
Women after menopause may experience desire changes alongside vaginal dryness, pain, sleep disruption, mood change, or hormone-related symptoms. Those factors can change the first treatment question.
The strongest bremelanotide evidence applies to the population actually studied. Women considering a compounded route outside that population should understand that the pivotal trial did not include everyone with low desire.
Timing and what to expect
The approved injection is used at least 45 minutes before anticipated activity. Nasal and troche timing comes from their own prescriptions; the injection number does not transfer.
An as-needed treatment still requires planning, storage, and realistic expectations. The medication does not create consent, attraction, privacy, energy, comfort, or relationship closeness by itself.
Do not redose because a precise internet onset passed. Final route instructions must define timing and maximum use.
Nausea, blood pressure, and safety
Nausea was the most common adverse reaction in the Vyleesi program. The label also addresses flushing, headache, vomiting, transient blood-pressure increase, heart-rate reduction, focal hyperpigmentation, pregnancy, delayed gastric emptying, and reduced oral naltrexone exposure.
The approved injection is contraindicated in uncontrolled hypertension or known cardiovascular disease. A different route does not make those active-level questions disappear, although exact event rates may differ.
Seek urgent help for chest pain, fainting, severe allergic symptoms, or concerning blood-pressure symptoms. Product-specific instructions should define route-local reactions and escalation.
Medication interactions
Delayed gastric emptying can affect absorption of oral medications with narrow timing or concentration requirements. The approved label specifically warns that bremelanotide can reduce exposure to oral naltrexone.
Antidepressants, antihypertensives, alcohol, other sexual-health medications, and anti-nausea drugs create different questions. Do not turn common forum combinations into a public protocol.
Medication-caused low desire should also prompt a discussion of the causal drug rather than automatically adding bremelanotide.
Price, supply, and access
Rebody's PT-141 nasal spray is $99.50 first month, then $199 per 5 mL bottle. PT-141 troches are $54.50 first month, then $109 per 8-count package for 1 mg; $59.50 first month, then $119 for 2 mg. The label determines how many prescribed uses each package contains.
Once live, compare package price, prescribed uses, cold shipping, storage, and refill timing. Vyleesi coverage and out-of-pocket cost should be checked through current sources rather than assumed.
Rebody lists both needle-free routes as available; treatment still requires a prescription.
Questions women ask
Does PT-141 increase libido?
The approved injection improved desire and distress scores in premenopausal women with acquired, generalized HSDD. Spray and troche outcomes are not established.
Is it female Viagra?
No. Viagra targets blood flow. Bremelanotide acts through central melanocortin pathways and was studied for desire.
Does it work after menopause?
The cited Vyleesi indication does not include postmenopausal women. The pivotal trial population was premenopausal.
Does it guarantee arousal or orgasm?
No. Those are distinct outcomes, and the pivotal evidence centered on desire and distress.
Which Rebody route is best?
Nasal is simplest to administer. Troche is the compact oral-dissolve alternative. Both deliver bremelanotide through a needle-free routine, with product-specific instructions and route evidence.
Bottom line
Bremelanotide is a real desire medication with phase 3 evidence in premenopausal women with acquired, generalized HSDD and distress. Rebody's nasal bottle makes the routine fast and needle-free; the mini troche makes it compact and oral-dissolve. Choose the form that protects spontaneity while keeping the prescribed route, timing, and population clear.
Keep reading
- As-Needed Libido Medication Formats for Women
- Needle-Free Intimacy Treatments for Women: Sprays and Troches
- PT-141 for Women: Desire, Distress, Timing, and Side Effects